Mises à jour récentes
  • The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040, claims Roots Analysis
    SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share
    For additional details, please visit
    https://www.rootsanalysis.com/reports/sarm1-inhibitors-market.html
    or email sales@rootsanalysis.com
    The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040, claims Roots Analysis SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share For additional details, please visit https://www.rootsanalysis.com/reports/sarm1-inhibitors-market.html or email sales@rootsanalysis.com
    0 Commentaires 0 parts
  • AI-based digital pathology gains interest due to automation, digitization of healthcare, shortage of pathologists, and increased demand for pathology servicesIn recent years, advancements in technology and emphasis on precision medicine have recently paved the path for the development of artificial intelligence (AI) based digital pathology techniques for quantitative and qualitative assessment of samples.

    For additional details, please visit
    https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market.html or email sales@rootsanalysis.com
    AI-based digital pathology gains interest due to automation, digitization of healthcare, shortage of pathologists, and increased demand for pathology servicesIn recent years, advancements in technology and emphasis on precision medicine have recently paved the path for the development of artificial intelligence (AI) based digital pathology techniques for quantitative and qualitative assessment of samples. For additional details, please visit https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market.html or email sales@rootsanalysis.com
    0 Commentaires 0 parts
  • The smart pharmaceutical and healthcare labels market is anticipated to grow at a CAGR of 16%, till 2035, claims Roots Analysis In order to overcome the limitations and challenges related to counterfeit drugs, researchers and industry stakeholders are gradually adopting smart pharmaceutical and healthcare labels, which offer multiple benefits over conventional labels.

    Roots Analysis has announced the addition of “Smart Pharmaceutical and Healthcare Labels Market, 2022-2035” report to its list of offerings.

    A smart label comprises of printed information, a bar code identifier and a small transponder. This transponder contains a processing chip and an antenna that allows physical objects to communicate with the tag reader (for instance, RFID reader). Smart labels offer several benefits, such as tracing and tracking products in a supply chain, tamper proofing, as well as discouraging counterfeiters from packaging fake drugs. In this context, it is worth mentioning that smart labelling technology can potentially save USD 0.8 - 1.5 million per year, per company, through their applications in inventory management.


    Key Market Insights

    More than 90 companies claim to offer smart pharmaceutical and healthcare labels, globally
    This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (less than 50 employees) players, which collectively represent more than 75% of the total smart label providers in pharmaceutical and healthcare sectors. Further, ~20% of firms were established post-2010.

    400+ patents related to smart pharmaceutical and healthcare labels were filed / granted, since 2015
    Based on intellectual property distribution across the world, R&D activity related to smart pharmaceutical and healthcare labels is largely concentrated in North America (over 65%), followed by Europe (10%). In addition, most of the patents have been granted patent (55%), followed by patent applications (44%).

    Partnership activity in this domain has increased at a significant pace, between 2018 and 2022
    The recent partnerships trend in this market indicates the growing interest of industry stakeholders. It is worth highlighting that majority of the deals were service alliances, representing around 41% of the total number of partnerships signed in the given time period.

    North America and Europe are anticipated to capture over 65% of the market share by 2035
    The markets in Asia-Pacific and Latin America are anticipated to grow at a relatively faster pace. In the long-term, the aforementioned regions are expected to collectively represent 33% of the total market share. In addition, RFID based smart labels are likely to capture more than 75% of the market share in 2035.


    For additional details, please visit https://www.rootsanalysis.com/reports/smart-labels-market.html or email sales@rootsanalysis.com


    The smart pharmaceutical and healthcare labels market is anticipated to grow at a CAGR of 16%, till 2035, claims Roots Analysis In order to overcome the limitations and challenges related to counterfeit drugs, researchers and industry stakeholders are gradually adopting smart pharmaceutical and healthcare labels, which offer multiple benefits over conventional labels. Roots Analysis has announced the addition of “Smart Pharmaceutical and Healthcare Labels Market, 2022-2035” report to its list of offerings. A smart label comprises of printed information, a bar code identifier and a small transponder. This transponder contains a processing chip and an antenna that allows physical objects to communicate with the tag reader (for instance, RFID reader). Smart labels offer several benefits, such as tracing and tracking products in a supply chain, tamper proofing, as well as discouraging counterfeiters from packaging fake drugs. In this context, it is worth mentioning that smart labelling technology can potentially save USD 0.8 - 1.5 million per year, per company, through their applications in inventory management. Key Market Insights More than 90 companies claim to offer smart pharmaceutical and healthcare labels, globally This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (less than 50 employees) players, which collectively represent more than 75% of the total smart label providers in pharmaceutical and healthcare sectors. Further, ~20% of firms were established post-2010. 400+ patents related to smart pharmaceutical and healthcare labels were filed / granted, since 2015 Based on intellectual property distribution across the world, R&D activity related to smart pharmaceutical and healthcare labels is largely concentrated in North America (over 65%), followed by Europe (10%). In addition, most of the patents have been granted patent (55%), followed by patent applications (44%). Partnership activity in this domain has increased at a significant pace, between 2018 and 2022 The recent partnerships trend in this market indicates the growing interest of industry stakeholders. It is worth highlighting that majority of the deals were service alliances, representing around 41% of the total number of partnerships signed in the given time period. North America and Europe are anticipated to capture over 65% of the market share by 2035 The markets in Asia-Pacific and Latin America are anticipated to grow at a relatively faster pace. In the long-term, the aforementioned regions are expected to collectively represent 33% of the total market share. In addition, RFID based smart labels are likely to capture more than 75% of the market share in 2035. For additional details, please visit https://www.rootsanalysis.com/reports/smart-labels-market.html or email sales@rootsanalysis.com
    1
    0 Commentaires 0 parts
  • The liposome development and manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis
    Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years.
    London

    Roots Analysis has announced the addition of “Liposome Manufacturing Market, 2022-2035” report to its list of offerings.

    Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.

    Key Market Insights

    More than 70 companies are currently offering services related to liposome development and manufacturing, globally
    Majority (74%) of the service providers offer formulation development services for liposomes. This is followed by players offering analytical method development (65%), liposome contract manufacturing (64%), and process development (61%) services.

    Close to 6,100 articles focused on liposomes, have been published in reputed scientific journals, since 2017
    More than 50% of the articles focused on liposomes were published post-2019. Popular journals that have published multiple articles include International Journal of Pharmaceutics, Journal of Controlled Release, and Pharmaceutics.

    More than 800 clinical trials have been registered for the evaluation of liposome-based therapeutics, worldwide
    The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 17%, during the period 2017-2021. Of the total number of trials registered, 60% have already been completed, while 26% of the studies are actively recruiting participants.

    Nearly 700 patents related to liposomes have been filed / granted, since 2017
    Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 55% of patent applications have been filed post-2016. It is worth noting that 61% patents related to liposomes were filed / granted in the US alone.

    Over 110 global events related to liposomes were organized in the past couple of years
    Majority (63%) of the events related to liposomes, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. Further, the agendas of the events organized post-2020 include discussions on the applications, and recent advancements in technologies associated with liposomes.

    For additional details, please visit
    https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html
    or email sales@rootsanalysis.com

    The liposome development and manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years. London Roots Analysis has announced the addition of “Liposome Manufacturing Market, 2022-2035” report to its list of offerings. Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers. Key Market Insights More than 70 companies are currently offering services related to liposome development and manufacturing, globally Majority (74%) of the service providers offer formulation development services for liposomes. This is followed by players offering analytical method development (65%), liposome contract manufacturing (64%), and process development (61%) services. Close to 6,100 articles focused on liposomes, have been published in reputed scientific journals, since 2017 More than 50% of the articles focused on liposomes were published post-2019. Popular journals that have published multiple articles include International Journal of Pharmaceutics, Journal of Controlled Release, and Pharmaceutics. More than 800 clinical trials have been registered for the evaluation of liposome-based therapeutics, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 17%, during the period 2017-2021. Of the total number of trials registered, 60% have already been completed, while 26% of the studies are actively recruiting participants. Nearly 700 patents related to liposomes have been filed / granted, since 2017 Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 55% of patent applications have been filed post-2016. It is worth noting that 61% patents related to liposomes were filed / granted in the US alone. Over 110 global events related to liposomes were organized in the past couple of years Majority (63%) of the events related to liposomes, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. Further, the agendas of the events organized post-2020 include discussions on the applications, and recent advancements in technologies associated with liposomes. For additional details, please visit https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html or email sales@rootsanalysis.com
    0 Commentaires 0 parts
Plus de lecture
G-6DD9N5G43R